Charnwood Molecular will be taking part in a forthcoming trade mission to Denmark, alongside its strategic partners.
The mission will be heading to Denmark on the 25th March 2015 on a market visit supported by UKTI and hosted at the residence of the British Ambassador in Copenhagen.
The market visit, entitled: “The Changing Face of Pharmaceutical Discovery and Development – A Collaborative CRO Approach” will provide an opportunity for life science research companies across the Nordik region to meet and discuss how collaborative outsourcing can overcome the key scientific challenges within R&D.
Charnwood Molecular has been keen in developing the approach and has seized the opportunity to promote the collaborative approach to win new business.
Aimed at R&D scientists, project leaders and resource managers, the meeting will consist of opening presentations reflecting on current trends in outsourcing worldwide with particular reference to Scandinavia.
Representatives from all CROs will give an overview of how their services are applied to problem solving within the R&D pipeline. Further discussion is then planned to explore opportunities.
“We aim to capitalise on the collaborative approach that this trip gives and places us ideally to help Nordik companies looking for support with their research projects,” states Dr Robin Wilkes, Business Development Director – Medicinal Chemistry at Charnwood Molecular. “We are keen to work together with these companies that naturally complement our services and this is another vehicle to do so.”
The companies attending complement Charnwood Molecular in their drug discovery activities and process development. Aurelia BioScience covers compound screening to identify hit and lead molecules. XenoGesis are specialists in drug metabolism and pharmacokinetics (DMPK) testing. Reach Separations provides the analytical and chromatographic expertise, particularly for chiral compounds. Molecular Profiles provides pharmaceutical development services and clinical trial manufacturing for small molecules and can work from early phase development to late stage clinical manufacture. Biopta addresses the issue of translational relevance, proving data from tailored fresh human tissue assay systems; interfacing with the other groups by testing novel molecules for efficacy, absorption or safety in healthy and diseased tissue.
The market visit follows a successful two-day visit to Switzerland last year organised and supported by UKTI.